NECTIN4 and neoplasm: Considering that Nectin-4 is weakly to moderately expressed in normal tissues of the skin (cell–cell adhesion role), one of the most EV-related adverse events is skin reactions, with 43.9% of patients reporting rash; among these patients, 14.5% ≥ grade 3 [26].